Saxagliptin is a type 2 diabetes medication that stimulates the pancreas to produce more insulin after meals. It was jointly developed by AstraZeneca and Bristol-Myers Squibb. It is a dipeptidyl peptidase-4 (DPP-IV) inhibitor. On July 31, 2009, AstraZeneca and Bristol-Myers Squibb jointly developed a new type 2 diabetes drug from Chemicalbook, saxagliptin (Onglyza), which was approved by the US FDA for marketing once a day for the treatment of adult type 2 diabetes. Control your diet and exercise more. The most common side effects are upper respiratory tract infection, urinary tract infection and headache, other side effects include allergic-like reactions such as rash and hives. The mechanism of action of saxagliptin works by blocking the degradation of GLP-1, a hormone naturally produced in the intestine after ingestion of food, which regulates insulin secretion and enhances the availability of glucose in surrounding tissues. Sark Chemicalbook liptin can improve blood sugar control alone, and it can enhance the efficacy when combined with metformin, sulfonylureas, and thiazolidinediones, and it has a lower risk of hypoglycemia, and the adverse reactions are similar to those of placebo. Good tolerance. Saxagliptin is a competitive inhibitor of dipeptidyl peptidase 4 (DPP4), which reduces the inactivation rate of incretin hormone and increases its blood concentration, thereby reducing fasting and meals in a glucose-dependent manner in patients with type 2 diabetes post-glucose concentration. After a meal, increased concentrations of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), are released from the small intestine into the blood, which promote pancreatic β-cell metabolism. Insulin is released in a glucose-dependent manner, and DPP4 inactivates it.